Staphylococcus aureus (also known as Staph) is among the most prevalent pathogens responsible for healthcare-associated infections. Staph is one of the principal causes of surgical site infection, where in a procedure like spinal fusion surgery, about 1 to 3 people in every 100 develop a surgical site infection.

Pfizer has developed an investigational vaccine staphylococcus aureus 4 –antigen (SA4Ag) to help prevent infections caused by staph. In collaboration with Pfizer, W21C and AHS are currently recruiting study patients for his phase 2, randomized, double-blinded, placebo-controlled study to evaluate the safety and efficacy of SA4Ag vaccine in adults undergoing elective posterior instrumented spinal fusion surgery.